Laboratory of Photochemistry and Bioinorganic Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Av. do Café, Vila Monte Alegre, Ribeirão Preto, São Paulo, 14040-903, Brazil.
Institute of Chemistry, São Paulo State University, Av. Prof. Francisco Degni, 55, 14800-900, Araraquara, São Paulo, Brazil.
Dalton Trans. 2024 Jul 9;53(27):11264-11275. doi: 10.1039/d4dt00381k.
Efforts to find compounds selectively affecting cancer cells while sparing normal ones have continued to grow. Nitric oxide (NO) is critical in physiology and pathology, including cancer. It influences cellular processes like proliferation, apoptosis, and angiogenesis. The intricate interaction of NO with cancer cells offers innovative treatment possibilities, but its effects can vary by concentration and site. Ruthenium complexes capable of releasing NO upon stimulation show for this purpose. These versatile compounds can also enhance photodynamic therapy (PDT), a light-activated approach, which induces cellular damage. Ruthenium-based photosensitizers (PSs), delivering NO and producing reactive oxygen species (ROS), offer a novel strategy for improved cancer treatments. In this study, a nitro-ruthenium porphyrin conjugate: {TPyP[Ru(NO)(bpy)]}(PF), designated RuNOTPyP, which releases NO upon irradiation, was investigated for its effects on lung cells (non-tumor MRC-5 and tumor A549) in 2D and 3D cell cultures. The findings suggest that this complex has potential for PDT treatment in lung cancer, as it exhibits photocytotoxicity at low concentrations without causing cytotoxicity to normal lung cells. Moreover, treatment of cells with RuNOTPyP followed by light irradiation (4 J cm) can induce apoptosis, generate ROS, promote intracellular NO formation, and has anti-migratory effects. Additionally, the complex can modify tumor cell structures and induce photocytotoxicity and apoptosis in a 3D culture. These outcomes are attributed to the internalization of the complex and its subsequent activation upon light irradiation, resulting in NO release and singlet oxygen production.
人们一直致力于寻找能够选择性地影响癌细胞而不影响正常细胞的化合物。一氧化氮(NO)在生理和病理过程中都至关重要,包括癌症。它影响细胞增殖、凋亡和血管生成等过程。NO 与癌细胞的复杂相互作用为创新治疗提供了可能,但它的效果可能因浓度和位置而异。能够在受到刺激时释放 NO 的钌复合物就是为此目的而设计的。这些多功能化合物还可以增强光动力疗法(PDT),一种光激活的方法,它会引起细胞损伤。释放 NO 并产生活性氧(ROS)的基于钌的光敏剂(PS)为改善癌症治疗提供了一种新策略。在这项研究中,研究了一种硝基钌卟啉缀合物:{TPyP[Ru(NO)(bpy)]}(PF),命名为 RuNOTPyP,它在受到照射时会释放 NO,研究了它对 2D 和 3D 细胞培养中的肺细胞(非肿瘤 MRC-5 和肿瘤 A549)的影响。研究结果表明,该复合物在肺癌的 PDT 治疗中具有潜力,因为它在低浓度下表现出光细胞毒性,而不会对正常肺细胞造成细胞毒性。此外,用 RuNOTPyP 处理细胞后再进行光照(4 J cm)可以诱导细胞凋亡、产生 ROS、促进细胞内 NO 的形成,并具有抗迁移作用。此外,该复合物可以修饰肿瘤细胞结构,并在 3D 培养中诱导光细胞毒性和细胞凋亡。这些结果归因于复合物的内化及其在光照下的后续激活,导致 NO 释放和单线态氧的产生。